Microtubule-Stabilizing Natural Products as Promising Cancer Therapeutics

Paclitaxel and related taxanes exhibit their anticancer activity by promoting tubulin polymerization and stabilizing microtubules, which results in mitotic G2/M arrest and apoptosis. The clinical success of paclitaxel in treating a wide array of tumor types has led to numerous efforts to identify no...

Full description

Saved in:
Bibliographic Details
Published inCurrent medicinal chemistry Vol. 14; no. 28; pp. 2959 - 2967
Main Author GALLAGHER, Brian M
Format Journal Article
LanguageEnglish
Published Schiphol Bentham Science Publishers Ltd 01.12.2007
Bentham Science
Subjects
Antineoplastic agents
Biological and medical sciences
Biological Products - chemistry
Biological Products - pharmacology
Biological Products - therapeutic use
Drug Design
General aspects
Humans
Medical sciences
Microtubules - drug effects
Mitosis - drug effects
Neoplasms - drug therapy
Pharmacology. Drug treatments
Tubulin - metabolism
Antineoplastic agent
Terpenoid
laulimalide
Microtubule-stabilizing
Stabilization
Taxol
antitumor
natural product
Lactone
discodermolide
Natural compound
Malignant tumor
Macrolide
Biological activity
Research and development
anticancer
Polyketide
Taxane derivatives
Paclitaxel
Diterpene
epothilone
Microtubule
Chemical synthesis
Cancer
Online AccessGet full text

Cover

More Information
Summary:Paclitaxel and related taxanes exhibit their anticancer activity by promoting tubulin polymerization and stabilizing microtubules, which results in mitotic G2/M arrest and apoptosis. The clinical success of paclitaxel in treating a wide array of tumor types has led to numerous efforts to identify novel natural products with paclitaxel-like mechanisms of action, but which may overcome some of the liabilities of the taxanes. Although the list of natural products that share the paclitaxel-like mechanism is relatively small, it continues to expand and currently includes a number of structurally distinct classes. Despite the mechanistic similarities between these classes, differences exist which may translate into their differential efficacy in the clinic. The past several years have seen a considerable amount of pre-clinical and clinical progress in developing these novel microtubule-stabilizing natural products as cancer therapeutics. This review focuses primarily on recent advances published since 2002.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0929-8673
1875-533X
DOI:10.2174/092986707782794014